Beyondspring Inc Receives a Buy from Maxim Group

By Austin Angelo

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Beyondspring Inc (NASDAQ: BYSI), with a price target of $52. The company’s shares opened today at $30.

McCarthy noted:

“BeyondSpring will be presenting P2 data (N=55) from study 105 comparing lead asset plinabulin to Neulasta on incidence of neutropenia. The data (detailed below) demonstrates that a single dose of Plinabulin protects against neutropenia at the same rate as Neulasta while producing lower rates of bone pain.”

According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 5.6% and a 45.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Beyondspring Inc has an analyst consensus of Moderate Buy, with a price target consensus of $56.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.49 and a one-year low of $19.55. Currently, Beyondspring Inc has an average volume of 14.66K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.